Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation A Phase 2 Study on Efficacy, Safety and Intratumoral Pharmacokinetics of Oral Selinexor (KPT-330) in Patients with Recurrent Glioblastoma (GBM) PDF (1.30 MB) Read MorePresentation A Phase 1b Study with Selinexor, a First in Class Selective Inhibitor of Nuclear Export (SINE) in Patients with Advanced Sarcomas: An Efficacy Analysis PDF (1.57 MB) Read MorePresentation Preliminary Phase II Results of Selinexor (KPT-‐330), an Oral Selective Inhibitor of Nuclear Export, in Patients with Heavily Pretreated Gynecological Cancers PDF (2.17 MB) Read MorePresentation PAK4 allosteric modulators (PAMs) repress the Wnt/?-catenin signaling pathway and tumor growth PDF (1.38 MB) Read MorePresentation Selinexor, a selective inhibitor of nuclear export (SINE), acts through NF-?B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death PDF (725.91 KB) Read MorePresentation Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows enhanced antitumor activity in combination with the PARP inhibitor, olaparib, in models of triple-negative breast cancer PDF (979.70 KB) Read MorePresentation Selinexor and melphalan combination therapy for the treatment of multiple myeloma PDF (2.97 MB) Read MorePresentation Inhibition of Pak4 blocks growth of breast cancer cells PDF (872.69 KB) Read MorePresentation Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells PDF (20.76 MB) Read MorePresentation Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cells in vitro and in vivo PDF (1.81 MB) Read More Previous 1 … 12 13 14 15 16 … 22 Next